GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Oncolytics Biotech Inc (TSX:ONC) » Definitions » Shiller PE Ratio

Oncolytics Biotech (TSX:ONC) Shiller PE Ratio : (As of May. 21, 2024)


View and export this data going back to 2000. Start your Free Trial

What is Oncolytics Biotech Shiller PE Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Oncolytics Biotech Shiller PE Ratio Historical Data

The historical data trend for Oncolytics Biotech's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Oncolytics Biotech Shiller PE Ratio Chart

Oncolytics Biotech Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Shiller PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Oncolytics Biotech Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Shiller PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Oncolytics Biotech's Shiller PE Ratio

For the Biotechnology subindustry, Oncolytics Biotech's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Oncolytics Biotech's Shiller PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Oncolytics Biotech's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Oncolytics Biotech's Shiller PE Ratio falls into.



Oncolytics Biotech Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

Oncolytics Biotech's E10 for the quarter that ended in Mar. 2024 is calculated as:

For example, Oncolytics Biotech's adjusted earnings per share data for the three months ended in Mar. 2024 was:

Adj_EPS=Earnings per Share (Diluted)/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=-0.09/126.2576*126.2576
=-0.090

Current CPI (Mar. 2024) = 126.2576.

Oncolytics Biotech Quarterly Data

Earnings per Share (Diluted) CPI Adj_EPS
201406 -0.475 99.473 -0.603
201409 -0.475 99.394 -0.603
201412 -0.380 98.367 -0.488
201503 -0.380 99.789 -0.481
201506 -0.285 100.500 -0.358
201509 -0.190 100.421 -0.239
201512 -0.285 99.947 -0.360
201603 -0.285 101.054 -0.356
201606 -0.190 102.002 -0.235
201609 -0.285 101.765 -0.354
201612 -0.440 101.449 -0.548
201703 -0.285 102.634 -0.351
201706 -0.320 103.029 -0.392
201709 -0.200 103.345 -0.244
201712 -0.320 103.345 -0.391
201803 -0.310 105.004 -0.373
201806 -0.270 105.557 -0.323
201809 -0.200 105.636 -0.239
201812 -0.280 105.399 -0.335
201903 -0.270 106.979 -0.319
201906 -0.260 107.690 -0.305
201909 -0.160 107.611 -0.188
201912 -0.830 107.769 -0.972
202003 -0.040 107.927 -0.047
202006 -0.170 108.401 -0.198
202009 -0.160 108.164 -0.187
202012 -0.220 108.559 -0.256
202103 -0.130 110.298 -0.149
202106 -0.130 111.720 -0.147
202109 -0.090 112.905 -0.101
202112 -0.140 113.774 -0.155
202203 -0.120 117.646 -0.129
202206 -0.090 120.806 -0.094
202209 -0.080 120.648 -0.084
202212 -0.150 120.964 -0.157
202303 -0.100 122.702 -0.103
202306 -0.120 124.203 -0.122
202309 -0.140 125.230 -0.141
202312 -0.050 125.072 -0.050
202403 -0.090 126.258 -0.090

Add all the adjusted EPS together and divide 10 will get our E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Oncolytics Biotech  (TSX:ONC) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.


Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.


Oncolytics Biotech Shiller PE Ratio Related Terms

Thank you for viewing the detailed overview of Oncolytics Biotech's Shiller PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Oncolytics Biotech (TSX:ONC) Business Description

Traded in Other Exchanges
Address
322 11th Avenue S.W, Suite 804, Calgary, AB, CAN, T2R 0C5
Oncolytics Biotech Inc is a development-stage biopharmaceutical company. The company is focused on the discovery and development of pharmaceutical products for the treatment of cancers that have not been treated with therapeutics. Its clinical development plan has the approval of its products as quickly as possible and expands its products into commercially valuable new treatment areas as objectives. The primary focus is to advance programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to phase 3 licensure-enabling studies.
Executives
Kirk Look Senior Officer

Oncolytics Biotech (TSX:ONC) Headlines

No Headlines